Eleven state treasurers, led by Pennsylvania, say they will pursue legal and legislative action if Gilead Science does not lower the cost of its COVID-19 treatment remdesivir. Gilead is prioritizing unreasonable profits over recovery and disregards the $70 million American taxpayers paid to study the drug as an Ebola treatment, the treasurers say in a Sept. 16 letter to Gilead CEO Daniel O’Day. In the United States, remdesivir’s price is capped at $3,120 per treatment course , even though Gilead...